SCHEMBL1130749

SCHEMBL1130749

COC(=O)COc1ccc(CC2SC(=O)N(C(c3ccccc3)(c3ccccc3)c3ccccc3)C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.47
ACSS2 Q9NR19 1/20 0.40
MPC2 O95563 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2C9 P11712 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MCL1 Q07820 1/20 0.39
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
FAAH O00519 1/20 0.38
PTPN1 P18031 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
FFAR1 O14842 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
ADAM17 P78536 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6177323 0.90 PTPN1 (0.45) PPARGMPC2CYP2C8CYP2C9MEN1
SCHEMBL8309388 0.90 PPARG (0.44) PPARGMPC2CYP2C8CYP2C9MEN1
SCHEMBL8857154 0.88 PPARG (0.43) PPARGMPC2CYP2C8CYP2C9MEN1
SCHEMBL8304179 0.83 MCL1 (0.41) PPARGMEN1KMT2APOLBMCL1
SCHEMBL27516237 0.80 MAPT (0.51) PPARGCYP2C9MEN1KMT2APOLB
SCHEMBL8405115 0.79 MTNR1A (0.38) PPARGPTPN1
SCHEMBL8405118 0.79 MTNR1A (0.38) PPARGPTPN1
SCHEMBL8306634 0.77 CTRB1 (0.41) MEN1KMT2A
SCHEMBL8563228 0.76 PPARG (0.39) PPARGCYP2C9MCL1MAPTKDM4E
SCHEMBL8305019 0.76 RECQL (0.42) PPARGSMN1; SMN2MAPTKDM4EFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0753298-B2 Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis SANKYO CO (JP) 2011-02-16 EP disclosed
EP-0753298-B1 Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis SANKYO CO (JP) 2001-11-21 EP disclosed
EP-0745600-B1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO CO (JP) 2001-10-24 EP disclosed
US-6159997-A Treatment of arteriosclerosis and xanthoma SANKYO COMPANY, LIMITED (JP) 2000-12-12 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5798375-A ADMINISTERING TO THE PATIENT PREVASTATIN A HYDROXY-3-METHYL-GLUTARYL/3-/ COENZYME A REDUCTASE INHIBITOR AND A INSULIN SENSITIZER TROGLITAZONE SANKYO COMPANY, LIMITED (JP) 1998-08-25 US disclosed
EP-0753298-A1 Synergistic combination comprising an insulin sensitizer and a HMG-CoA reductase inhibitor for treating arteriosclerosis SANKYO COMPANY LIMITED (JP) 1997-01-15 EP disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed